Details for Patent: 11,395,889
✉ Email this page to a colleague
Which drugs does patent 11,395,889 protect, and when does it expire?
Patent 11,395,889 protects QVAR REDIHALER and is included in one NDA.
This patent has one hundred and ninety-two patent family members in twenty-four countries.
Summary for Patent: 11,395,889
| Title: | Dose counter for inhaler having an anti-reverse rotation actuator |
| Abstract: | An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler. |
| Inventor(s): | Declan Walsh, Derek Fenlon, Simon Kaar, Jan Geert Hazenberg, Daniel Buck, Paul Clancy, Robert Charles Uschold, Jeffrey A. Karg |
| Assignee: | Teva Pharmaceuticals Ireland , Ivax Pharmaceuticals Ireland , Norton Waterford Ltd |
| Application Number: | US16/915,558 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,395,889 |
|
Patent Claim Types: see list of patent claims | Delivery; |
Drugs Protected by US Patent 11,395,889
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norton Waterford | QVAR REDIHALER | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 207921-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Norton Waterford | QVAR REDIHALER | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 207921-002 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,395,889
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011254958 | ⤷ Start Trial | |||
| Brazil | 112012029106 | ⤷ Start Trial | |||
| Canada | 2799625 | ⤷ Start Trial | |||
| Canada | 2887315 | ⤷ Start Trial | |||
| Canada | 2936362 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
